Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629228 | 0.84 | CYP19A1 (0.46) | KDM4EMEN1ALDH1A1LMNAGAA | |
| SCHEMBL874528 | 0.79 | RAB9A (0.72) | RAB9AKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL9629237 | 0.78 | ALOX5 (0.62) | KDM4EMEN1ALDH1A1LMNAGAA | |
| SCHEMBL13801090 | 0.76 | APP (0.61) | RAB9AMEN1ALDH1A1LMNAGAA | |
| SCHEMBL9630614 | 0.76 | KDM4E (0.72) | KDM4EMEN1ALDH1A1LMNAGAA | |
| SCHEMBL19757223 | 0.75 | APP (0.52) | RAB9AKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9629266 | 0.75 | ALOX5 (0.63) | — | |
| SCHEMBL9629280 | 0.75 | MAPT (0.58) | KDM4EMEN1ALDH1A1LMNAGAA | |
| SCHEMBL9629483 | 0.75 | ALOX5 (0.58) | KDM4EMEN1ALDH1A1LMNAGAA | |
| SCHEMBL9628607 | 0.75 | KDM4E (0.58) | KDM4EMEN1ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| CN-103703005-A | Tricyclic inhibitors of kinases | ABBOTT LAB | 2014-04-02 | — | — | CN | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-5124342-A | Antiinflammatory, antiarthritic agents; antiallergens; skin disorders | ABBOTT LABORATORIES (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0457803-A4 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | — | 1991-12-04 | — | — | EP | disclosed |
| EP-0457803-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-11-27 | — | — | EP | disclosed |
| WO-1990009801-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-09-07 | — | — | WO | disclosed |
| WO-1990009381-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | RAB9A 2519/4885KDM4E 482/4885MEN1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.